Principais Descobertas do SIRFLOX


Microsferas de resina SIR-Spheres® Y-90 + mFOLFOX6 (+ bev*) em mCRC

  • Nenhuma melhoria estatisticamente significativa da PFS em nenhum local.1
  • Melhoria estatisticamente significativa de 7,9 meses na PFS mediana no fígado, de 12,6 para 20,5 meses, representando uma redução de 31% do risco de progressão no fígado.1
  • Aumento estatisticamente significativo de 20% na Profundidade de Resposta (DpR) hepática em pacientes com carga tumoral >12% e melhoria >100 dias no Tempo de Nadir em comparação com a quimioterapia sozinha.2
  • Aumento de três vezes na taxa de resposta completa no fígado.1
  • Aumento estatisticamente significativo na taxa de resposta hepática.1

bev*: bevacizumab (bevacizumab permitido a critério do pesquisador, de acordo com as práticas institucionais)
1. van Hazel GA et al. J Clin Oncol 2016; 34: 1723–1731.
2. Heinemann V et al. ESMO WCGIC, Annals of Oncology 2016; 27 (Suppl 2): Abs. O-014.


Os dados SIRFLOX foram apresentados na ASCO 2015 pelo Professor Peter Gibbs, do Royal Melbourne Hospital, Austrália, co-investigador principal.


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×